Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Onychomycosis (Tinea Unguium)-Pipeline Review, H1 2015

Onychomycosis (Tinea Unguium)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Onychomycosis (Tinea Unguium)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Onychomycosis (Tinea Unguium)-Pipeline Review, H1 2015', provides an overview of the Onychomycosis (Tinea Unguium)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Onychomycosis (Tinea Unguium) Overview 8

Therapeutics Development 9

Pipeline Products for Onychomycosis (Tinea Unguium)-Overview 9

Pipeline Products for Onychomycosis (Tinea Unguium)-Comparative Analysis 10

Onychomycosis (Tinea Unguium)-Therapeutics under Development by Companies 11

Onychomycosis (Tinea Unguium)-Therapeutics under Investigation by Universities/Institutes 13

Onychomycosis (Tinea Unguium)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Onychomycosis (Tinea Unguium)-Products under Development by Companies 18

Onychomycosis (Tinea Unguium)-Products under Investigation by Universities/Institutes 19

Onychomycosis (Tinea Unguium)-Companies Involved in Therapeutics Development 20

Actavis plc 20

Anacor Pharmaceuticals, Inc. 21

Eisai Co., Ltd. 22

Evolva SA 23

Helix BioMedix, Inc. 24

Mayne Pharma Group Limited 25

Meiji Seika Pharma Co., Ltd. 26

Moberg Pharma AB 27

NAL Pharmaceuticals Ltd. 28

Nihon Nohyaku Co., Ltd. 29

Novabiotics Ltd 30

Nuvo Research Inc. 31

Viamet Pharmaceuticals, Inc. 32

Onychomycosis (Tinea Unguium)-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

albaconazole-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AN-2718-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

E-1224-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ELS-160-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

EV-086-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

HB-1275-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

itraconazole-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

luliconazole-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

ME-1111-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

NAL-3216-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

NP-213-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules for Fungal Infections-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

terbinafine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

terbinafine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

VT-1161-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Onychomycosis (Tinea Unguium)-Recent Pipeline Updates 64

Onychomycosis (Tinea Unguium)-Dormant Projects 70

Onychomycosis (Tinea Unguium)-Discontinued Products 72

Onychomycosis (Tinea Unguium)-Product Development Milestones 73

Featured News & Press Releases 73

Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 73

Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 73

Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 74

May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 75

Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 75

Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap 75

Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting 76

Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin 77

Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015 77

Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application 78

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 80

Disclaimer 80

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2015 9

Number of Products under Development for Onychomycosis (Tinea Unguium)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Investigation by Universities/Institutes, H1 2015 19

Onychomycosis (Tinea Unguium)-Pipeline by Actavis plc, H1 2015 20

Onychomycosis (Tinea Unguium)-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 21

Onychomycosis (Tinea Unguium)-Pipeline by Eisai Co., Ltd., H1 2015 22

Onychomycosis (Tinea Unguium)-Pipeline by Evolva SA, H1 2015 23

Onychomycosis (Tinea Unguium)-Pipeline by Helix BioMedix, Inc., H1 2015 24

Onychomycosis (Tinea Unguium)-Pipeline by Mayne Pharma Group Limited, H1 2015 25

Onychomycosis (Tinea Unguium)-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 26

Onychomycosis (Tinea Unguium)-Pipeline by Moberg Pharma AB, H1 2015 27

Onychomycosis (Tinea Unguium)-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 28

Onychomycosis (Tinea Unguium)-Pipeline by Nihon Nohyaku Co., Ltd., H1 2015 29

Onychomycosis (Tinea Unguium)-Pipeline by Novabiotics Ltd, H1 2015 30

Onychomycosis (Tinea Unguium)-Pipeline by Nuvo Research Inc., H1 2015 31

Onychomycosis (Tinea Unguium)-Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Mechanism of Action, H1 2015 37

Number of Products by Stage and Route of Administration, H1 2015 39

Number of Products by Stage and Molecule Type, H1 2015 41

Onychomycosis (Tinea Unguium) Therapeutics-Recent Pipeline Updates, H1 2015 64

Onychomycosis (Tinea Unguium)-Dormant Projects, H1 2015 70

Onychomycosis (Tinea Unguium)-Dormant Projects (Contd..2), H1 2015 71

Onychomycosis (Tinea Unguium)-Discontinued Products, H1 2015 72

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2015 9

Number of Products under Development for Onychomycosis (Tinea Unguium)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 35

Number of Products by Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Top 10 Routes of Administration, H1 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 39

Number of Products by Top 10 Molecule Types, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

Anacor Pharmaceuticals, Inc.

Eisai Co., Ltd.

Evolva SA

Helix BioMedix, Inc.

Mayne Pharma Group Limited

Meiji Seika Pharma Co., Ltd.

Moberg Pharma AB

NAL Pharmaceuticals Ltd.

Nihon Nohyaku Co., Ltd.

Novabiotics Ltd

Nuvo Research Inc.

Viamet Pharmaceuticals, Inc.

Onychomycosis (Tinea Unguium) Therapeutic Products under Development, Key Players in Onychomycosis (Tinea Unguium) Therapeutics, Onychomycosis (Tinea Unguium) Pipeline Overview, Onychomycosis (Tinea Unguium) Pipeline, Onychomycosis (Tinea Unguium) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com